Speaker Profile
Biography
Alexis C. Komor is a pioneering genome‑editing researcher who co‑developed the first CRISPR base editors with David Liu at the Broad Institute. Her work established base editing as a new class of genome engineering tools that enable precise single‑nucleotide changes in DNA without double‑strand breaks, laying the foundation for correcting disease‑causing point mutations with high precision. She continues to lead efforts to translate these innovations into direct in vivo therapeutics, including strategies to deliver base editors via mRNA and other nucleic‑acid platforms to repair genes within patients’ cells. As her work established the scientific foundation of Beam Therapeutics, Komor has helped drive the clinical development of base editing, underscoring the broad impact of her work on programmable gene editing and precision medicine. Her groundbreaking contributions are influencing a new generation of in vivo RNA and gene‑based therapies (spanning mRNA, siRNA, and antisense oligonucleotide modalities) and inspiring novel small‑molecule approaches to treat genetic diseases.
Talk
Development and Characterization of Precision Genome Editing Tools
Base editors facilitate the introduction of point mutations into the genome of live cells with high efficiencies and precision via targeted nucleobase chemistry. In this talk I will describe my lab's efforts to develop new base editing methodologies and their application to correcting disease-causing mutations.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair: Catriona Jamieson, UCSD
PMWC Award Ceremony Honorees
• Judy Faulkner, Epic
• Svetlana Mojsov, The Rockefeller University (GLP-1)
• Alexis C. Komor, UCSD
Opening Talk
• Catriona Jamieson, UC San Diego
GLP-1: From Hormone Discovery to a Global Therapeutic Revolution
• Svetlana Mojsov, The Rockefeller University
What’s Next at Epic?
• Peter DeVault, Epic
Modified mRNA, siRNA, ASOs
• Chair: Alexis C. Komor, UC San Diego
• Niren Murthy, UC Berkeley
• Gene Yeo, UC San Diego
• Reuben Harris, UT Health San Antonio
Stem Cell–Targeted Therapeutics: Small Molecules & Biologics
• Chair: Catriona Jamieson, UC San Diego
• Irving L. Weissman, Stanford
In Vivo Gene Therapies
• Chair: Gene Yeo, UC San Diego
• Mark A. Kay, Stanford
• David Schaffer, UC Berkeley
Diagnostics, Prognostics, and Patient Stratification
• Chair: Ezra Cohen, Tempus
• Eitan Ruppin, NIH
• Danielle Hamel, Tempus
• David Ledbetter, Florida State University
• Ludmil Alexandrov, UC San Diego
Closing
• Catriona Jamieson, UC San Diego




